About Cabrellis Pharmaceuticals
Cabrellis Pharmaceuticals is a Healthcare company based in Summit (United States) founded in 1986, and was acquired by Pharmion in November 2006. Small molecule therapeutics for cancer treatment are developed. Cabrellis Pharmaceuticals has raised $27.5 million across 1 funding round from investors including Pharmion, Domain Associates and Forward Ventures. Cabrellis Pharmaceuticals offers products and services including Pasta, Oils & Vinegar, Olives, Flour, and Tomatoes. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is Cabrelli LTD. Its competitors include C4 Therapeutics, Erasca and Revolution Medicines; 3 of its 3 listed competitors have raised funding.
Company details
Cabrellis Pharmaceuticals was founded in 1986 and is based in Summit, United States. Focus is placed on the development of small molecule therapeutics targeting cancer. Operations center on pharmaceutical research in oncology, with the lead candidate amrubicin identified as a third-generation anthracycline. Indications for amrubicin include both small-cell and non-small-cell lung cancer, supporting therapeutic advancements in this sector.
- Headquarters Summit, United States
- Stage Acquired
- SectorsHealthcare
- Website cabrellis.com
- Social LinkedIn Facebook
- Acquired by Pharmion (Nov 2006)
- Legal Name Cabrelli Ltd
Products & Services of Cabrellis Pharmaceuticals
Cabrellis Pharmaceuticals offers a comprehensive portfolio of products and services, including Pasta, Oils & Vinegar, Olives, Flour, and Tomatoes.
Authentic Italian pasta for restaurant culinary applications.
High-quality Italian oils and vinegar for cooking and dressings.
Premium Italian olives used in various dishes and appetizers.
Traditional Italian flour for baking and food preparation.
Authentic Italian tomatoes for sauces, salads, and recipes.
Funding Insights of Cabrellis Pharmaceuticals
Cabrellis Pharmaceuticals has successfully raised a total of $27.5M through 1 strategic funding round. The most recent funding activity was a Series A round of $27.5 million completed in August 2006. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $27.5M
- Total Rounds 1
- Last Round Series A — $27.5M
- First Round $27.5M
(Aug 2006)
- Investors Count 8
All 1 funding rounds of Cabrellis Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2006 | $27.5M | Series A | – | – |
9 investors in total: 9 institutional.
Investors in Cabrellis Pharmaceuticals
Cabrellis Pharmaceuticals has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Pharmion, Domain Associates and Forward Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life science & tech focused VC firm investing in the US | domainvc.com | Princeton, United States | ||
Life Sciences focused VC firm that does early stage investments in the US | forwardventures.com | San Diego, United States | ||
| proquestvc.com | ||||
A biotechnology venture capital firm investing in innovative science. | srone.com | |||
Early-stage life sciences investments are targeted in the healthcare sector. | lillyventures.com | Indianapolis, United States | ||
| rivervest.com | ||||
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
| rbccm.com | ||||
Therapies for the treatment of hematology and oncology disorders | 2000 | pharmion.com | Boulder, United States |
Investor details for Cabrellis Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Cabrellis Pharmaceuticals
3 dated milestones of Cabrellis Pharmaceuticals across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Cabrellis Pharmaceuticals is founded.
- Funding First funding round of $27.5M.
- Exit Acquired by Pharmion.
Competitors of Cabrellis Pharmaceuticals
Cabrellis Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and Revolution Medicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. |
Detailed competitors of Cabrellis Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Cabrellis Pharmaceuticals (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cabrellis Pharmaceuticals
Complete news archive for Cabrellis Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cabrellis Pharmaceuticals
Cabrellis Pharmaceuticals was founded in 1986 and raised its 1st funding round 20 years after it was founded.
Cabrellis Pharmaceuticals is headquartered in Summit, United States.
Cabrellis Pharmaceuticals is a funded company, having raised a total of $27.5M across 1 funding round to date. The company's 1st funding round was a Series A of $27.5M, raised on Aug 2006.
Cabrellis Pharmaceuticals was founded in 1986 and is based in Summit, United States. Focus is placed on the development of small molecule therapeutics targeting cancer. Operations center on pharmaceutical research in oncology, with the lead candidate amrubicin identified as a third-generation anthracycline. Indications for amrubicin include both small-cell and non-small-cell lung cancer, supporting therapeutic advancements in this sector.
Cabrellis Pharmaceuticals's top competitors include C4 Therapeutics, Erasca and Revolution Medicines.
Cabrellis Pharmaceuticals offers Pasta, Oils & Vinegar, Olives, Flour, and Tomatoes.
Cabrellis Pharmaceuticals has 9 investors. Key investors include Pharmion, Domain Associates, Forward Ventures, ProQuest Investments, and RBC Capital Markets.
Cabrellis Pharmaceuticals operates through Cabrelli Ltd.
Yes. Cabrellis Pharmaceuticals was acquired by Pharmion in November 2006.